Plain-English translation of NCT04985435 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether letting patients choose their own rheumatoid arthritis medication—specifically between (an oral tablet) or a TNF inhibitor (an injection)—leads to better satisfaction and long-term adherence compared to being randomly assigned one of these treatments. The study wants to understand what patients actually prefer and whether having a choice makes a real difference in how well people stick with their medication and how much their arthritis improves.
Many people with rheumatoid arthritis stop taking or don't fully follow their prescribed treatments, which reduces effectiveness. Recent guidelines emphasize 'shared decision-making'—letting patients have a voice in choosing their treatment. This trial exists to see whether giving patients the power to choose between treatment options helps them feel more satisfied, stay on their medication longer, and see better health outcomes.
You likely qualify if…
You likely don't qualify if…
You will be in the study for 24 weeks (about 6 months). Half of participants will watch a neutral information video about both medications and then choose which one they want to take; the other half will be randomly assigned to one of the two medications. You'll take your chosen or assigned medication and have regular clinic visits where your arthritis symptoms, physical activity, and overall well-being will be monitored through questionnaires and possibly a fitness tracker to see how the treatment affects your disease and daily life.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Netherlands